Zytiga 250 mg Tablets

Abiraterone Acetate belongs to a class of medications known as androgen synthesis inhibitors, which work by blocking an enzyme called CYP17, involved in the production of androgens not only in the testes but also in the adrenal glands and within the tumor tissue itself. This broader blockade of androgen production makes it particularly useful for prostate cancer that continues to progress despite standard hormone therapies targeting only testicular testosterone production. It is commonly used in the treatment of metastatic castration-resistant prostate cancer, often in combination with a corticosteroid like prednisone to help manage its hormonal effects and support overall treatment tolerability. As an oral targeted hormone therapy, Abiraterone tablets offer a convenient treatment option, allowing much of the treatment to take place at home between clinical check-ins. The tablets are typically taken once daily on an empty stomach, following a schedule established by an oncologist or urologist based on the patient's specific condition and treatment history. Regular monitoring, including prostate-specific antigen (PSA) level checks, liver function tests, and blood pressure monitoring, is an important part of treatment to help track response and ensure safety. Many patients experience meaningful disease control and improved quality of life with consistent use of Abiraterone as part of their treatment plan. As with all targeted hormone therapies for prostate cancer, Abiraterone Acetate tablets should be used strictly under the guidance of an experienced oncology or urology healthcare provider.